UK-based medical endowment Wellcome Trust is creating a £200m ($300m) investment company to invest in start-up biotechnology companies. The company, temporarily called Sigma, will focus on UK and European transformational technologies with potential for high returns over at least a decade. Nigel Keen, chairman of public technology companies in the healthcare and electronics industries, including Oxford Instruments, Laird, Bioquell and Deltex Medical, will be chairman of Sigma. Martin Murphy (pictured), previously a partner at venture capital firm MVM Life Science Partners where he led its European deals such as PregLem and Heptares Therapeutics, will be chief executive of Sigma. Wellcome has been increasingly active in its direct equity investments as a quasi-corporate venturing unit having been formed out of its share ownership of the drug company that has since become GlaxoSmithKline. In December, Wellcome said it had raised its venture and growth capital holdings to 19% of its £13.6bn investment portfolio and posted a 17% return in 2011. Glyn Edwards, interim chief executive of the BioIndustry Association, said: "The Wellcome Trust’s decision to launch a fund focussed on long-term investment in biotechnology start-ups should provide a significant boost to companies developing new medicines. Given the time required to bring innovative healthcare developments to market, it is especially pleasing to see that the fund will take a long term view and provide companies with the support they need to reach their full potential."
- News & Analysis
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Deal Data
- Community & Events
Healthcare welcomes latest fund
Mar 20, 2012 • James Mawson
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Featured ContentFUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database.
FUNDING ROUND DATA
Which corporates are backing which startups? Search our corporate deal database.NOMINATE Nominations for the GCV Powerlist 2024 are now open
Nominations for the GCV Powerlist 2024 are now openEventsWebinar: Startups and Strategics – What works and what doesn’tEventsGCV Institute: Landing the Value of Corporate VenturingTop News
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.test reg